Scholarlink

<p>Accurate pathological response assessment of breast cancer following neoadjuvant therapy (NAT) is clinically critical but lacks robust imaging methods, so this study evaluated the diagnostic accuracy of <sup>18</sup>F-fluorodeoxyglucose (FDG) PET/CT and <sup>68</sup>Ga-fibroblast activation protein inhibitor (FAPI) PET/CT in clinically node positive (cN+) breast cancer patients receiving NAT. This prospective study enrolled pathologically confirmed breast cancer patients who underwent NAT and both PET/CT scans preoperatively. The maximum standardized uptake value (SUVmax) was measured and an optimal <sup>68</sup>Ga-FAPI PET/CT threshold was determined via receiver operating characteristic (ROC) curve analysis. Among 75 patients, 33 (44.0%) achieved pathological complete response (pCR). SUVmax was significantly lower in the ypT0/Tis group compared to the ypT+ group for both <sup>18</sup>F-FDG PET/CT (1.45 ± 0.55 vs. 5.19 ± 4.69, <i>p</i> &lt; 0.001) and <sup>68</sup>Ga-FAPI PET/CT (1.59 ± 1.22 vs. 10.45 ± 8.54, <i>p</i> &lt; 0.001). In the overall cohort, <sup>68</sup>Ga-FAPI PET/CT demonstrated higher sensitivity in detecting residual disease compared to <sup>18</sup>F-FDG PET/CT (0.8 vs. 0.6, <i>p</i> = 0.003), with comparable specificity (0.9 vs. 0.9, <i>p</i> = 1.00). Exploratory subgroup analysis found that <sup>68</sup>Ga-FAPI PET/CT had superior sensitivity compared to <sup>18</sup>F-FDG PET/CT in the hormone receptor-positive (HR + ) group (0.8 vs. 0.6, <i>p</i> = 0.02). These findings show that <sup>68</sup>Ga-FAPI PET/CT outperforms <sup>18</sup>F-FDG PET/CT in identifying residual breast lesions after NAT in cN+ patients, particularly among HR+ patients, which would guide further treatment strategies after NAT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic Performance of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Siji Zhu,
  • Yihua Jin,
  • Chao Hu,
  • Yanli Fan,
  • Xiaochun Fei,
  • Jiajia Hu,
  • Xiaosong Chen

摘要

Accurate pathological response assessment of breast cancer following neoadjuvant therapy (NAT) is clinically critical but lacks robust imaging methods, so this study evaluated the diagnostic accuracy of 18F-fluorodeoxyglucose (FDG) PET/CT and 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT in clinically node positive (cN+) breast cancer patients receiving NAT. This prospective study enrolled pathologically confirmed breast cancer patients who underwent NAT and both PET/CT scans preoperatively. The maximum standardized uptake value (SUVmax) was measured and an optimal 68Ga-FAPI PET/CT threshold was determined via receiver operating characteristic (ROC) curve analysis. Among 75 patients, 33 (44.0%) achieved pathological complete response (pCR). SUVmax was significantly lower in the ypT0/Tis group compared to the ypT+ group for both 18F-FDG PET/CT (1.45 ± 0.55 vs. 5.19 ± 4.69, p < 0.001) and 68Ga-FAPI PET/CT (1.59 ± 1.22 vs. 10.45 ± 8.54, p < 0.001). In the overall cohort, 68Ga-FAPI PET/CT demonstrated higher sensitivity in detecting residual disease compared to 18F-FDG PET/CT (0.8 vs. 0.6, p = 0.003), with comparable specificity (0.9 vs. 0.9, p = 1.00). Exploratory subgroup analysis found that 68Ga-FAPI PET/CT had superior sensitivity compared to 18F-FDG PET/CT in the hormone receptor-positive (HR + ) group (0.8 vs. 0.6, p = 0.02). These findings show that 68Ga-FAPI PET/CT outperforms 18F-FDG PET/CT in identifying residual breast lesions after NAT in cN+ patients, particularly among HR+ patients, which would guide further treatment strategies after NAT.